The goal of this interventional study is to compare the clinical outcomes of shortened 4-infusion course versus the standard 8-infusion course of Teprotumumab (Tepezza) in patients with active Thyroid Eye Disease (TED).

The main question it aims to answer is:

* Is a shorter course equally effective and safe for patients who respond well early in treatment.

Participants who demonstrate an early clinical response as part of their treatment with Teprotumumab will receive a shorter protocol of 4 infusions instead of the standard 8.

Inclusion Criteria:

• Participants must have a confirmed diagnosis of active Thyroid Eye Disease (TED).
• Participants must be eligible for and have started the standard Teprotumumab (Tepezza) treatment protocol.
• Participants must demonstrate a significant clinical response by the 4th infusion.
• Ability to understand and provide signed written informed consent.

Exclusion Criteria:

• Previous use of Teprotumumab or other biologic therapies for TED.
• Participants who do not show early clinical response after the 4th infusion.
• Participants who have any medical contraindications to Teprotumumab or any of its components.
• Participants who have any known hearing problems.